Is your child living with Congenital Hyperinsulinism?

Xeris Pharmaceuticals is currently seeking volunteers for a clinical research study for infants with Congenital Hyperinsulinism (HI).

About half of children with HI respond to standard medications, while others need additional treatment such as surgery. Glucagon is a natural substance produced by the body in response to low blood sugar. 


SUBMIT

See if your child may qualify:

In order to qualify, the participant must: 

  • Be diagnosed with Congenital Hyperinsulinism
  • Require intravenous glucose to prevent hypoglycemia
  • Be less than 12 months of age at screening

For more information on participating in this study, call (844) 311-3330.

Are you considering treatment options?

Travel arrangements are available can can be organized for your family. All or part of the cost of travel for qualified volunteers may be covered by the study Sponsor.

For more information on participating in this study, call (844) 311-3330.

This study is aiming to test how effective a new version of glucagon, called CSI-Glucagon (continuous subcutaneous glucagon infusion), is in maintaining normal glucose levels in informations with HI when it is delivered  with and OmniPod pump. Those who qualify may receive no-cost study-related treatment.

Fix the following errors:
Hide